SynthesisPloS one2016
A Systematic Review of the Prevalence and Pattern of Imaging Defined Post-TB Lung Disease.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Prevalence and associated factors of post-tuberculosis lung disease in Sub-Saharan Africa: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- A Systematic Review of Chronic Pulmonary Aspergillosis Among Patients Treated for Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Pooled it
- panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe.Trials · 2026Trial
- DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis.BMC infectious diseases · 2025Trial
- A novel inflammation-nutrition risk score (INRS) and its related nomogram model to predict radiological bronchiectasis in patients after tuberculosis infection in Wuhan, China.Annals of medicine · 2026Article
- Pulmonary tuberculosis and the surgeon.Lung India : official organ of Indian Chest Society · 2026Article
- Severe Post-Tuberculosis Bronchiectasis With Bullous Lung Disease Complicated by Acute Infective Exacerbation: A Case Report From Uganda.Clinical case reports · 2026Article
- Systemic Gaps and Roadmap for Integrated Care for Post-tuberculosis Lung Disease in Ethiopia: A Narrative Review.Cureus · 2026Review
- Preserved Ratio Impaired Spirometry in Low- and Middle-Income Countries: An Emerging Cardiopulmonary Phenotype and Cardiovascular Risk-A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances.Infection and immunity · 2026Review
- Host Serum Biomarker Signatures in Mycobacteriologically Cured Pulmonary Tuberculosis Patients with Persistent Lung Inflammation on 18F-FDG PET/CT.Diseases (Basel, Switzerland) · 2026Article
- Article
- From granulomas to tumors: post-tuberculosis immune and structural lung remodeling as a driver of carcinogenesis.Frontiers in immunology · 2026Review
- Post-tuberculosis lung disease.Breathe (Sheffield, England) · 2026Review
- Mortality hazards after treatment completion of pulmonary tuberculosis in a tertiary hospital in Uganda.IJID regions · 2025Article
- Collagen-targeted PET/CT imaging of tuberculosis patients.The European respiratory journal · 2025Article
- Clinical diagnosis of TB: lessons on misdiagnosis and overdiagnosis.Public health action · 2025Article
- Post-tuberculosis lung disease: towards prevention, diagnosis, and care.The Lancet. Respiratory medicine · 2025Review
- Pulmonary Nontuberculous Mycobacteria Infection in Bronchiectasis: A Narrative Review of Current Status and Future.Health science reports · 2025Article
- Sequelae of Immunocompromised Host Pneumonia.Clinics in chest medicine · 2025Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundTuberculosis is an important risk factor for chronic respiratory disease in resource poor settings. The persistence of abnormal spirometry and symptoms after treatment are well described, but the structural abnormalities underlying these changes remain poorly defined, limiting our ability to phenotype post-TB lung disease in to meaningful categories for clinical management, prognostication, and ongoing research. The relationship between post-TB lung damage and patient-centred outcomes including functional impairment, respiratory symptoms, and health related quality of life also remains unclear.
methodsWe performed a systematic literature review to determine the prevalence and pattern of imaging-defined lung pathology in adults after medical treatment for pleural, miliary, or pulmonary TB disease. Data were collected on study characteristics, and the modality, timing, and findings of thoracic imaging. The proportion of studies relating imaging findings to spirometry results and patient morbidity was recorded. Study quality was assessed using a modified Newcastle-Ottowa score. (Prospero Registration number CRD42015027958).
resultsWe identified 37 eligible studies. The principle features seen on CXR were cavitation (8.3-83.7%), bronchiectasis (4.3-11.2%), and fibrosis (25.0-70.4%), but prevalence was highly variable. CT imaging identified a wider range of residual abnormalities than CXR, including nodules (25.0-55.8%), consolidation (3.7-19.2%), and emphysema (15.0-45.0%). The prevalence of cavitation was generally lower (7.4-34.6%) and bronchiectasis higher (35.0-86.0%) on CT vs. CXR imaging. A paucity of prospective data, and data from HIV-infected adults and sub-Saharan Africa (sSA) was noted. Few studies related structural damage to physiological impairment, respiratory symptoms, or patient morbidity.
conclusionsPost-TB structural lung pathology is common. Prospective data are required to determine the evolution of this lung damage and its associated morbidity over time. Further data are required from HIV-infected groups and those living in sSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.